Profiles of Plasminogen Activator Inhibitor-1 Levels in Healthcare Workers with Latent Tuberculosis and Non-Latent Tuberculosis Infections (Healthy Control)
DOI:
https://doi.org/10.3889/oamjms.2022.10466Keywords:
Tuberculosis, Latent TB, PAI-1, COVID-19, Healthcare workersAbstract
Background: Mycobacterium tuberculosis infection causes the release of proinflammatory cytokines; interleukin IL-1, IL-6, and IL-8, as well as tumor necrosis factor (TNF-α), affecting hemostasis, namely an increase in procoagulation activity, a decrease in anticoagulant factors, and suppression of the fibrinolytic system that causes hypercoagulable states.
Methods: This is a cross-sectional study that involves 80 healthcare workers. The study was conducted in two academic medical centers that were part of the healthcare system of Makassar city, South Sulawesi province, Indonesia, from September to October 2021. PAI-1 levels were measured using the enzyme-linked immunosorbent assay technique. The statistical test results were significant if the p values were <0.05.
Results: Although there was no statistically significant difference (P > 0.05) in PAI-1 levels, PAI-1 level among participants in the LTBI group was found to be lower (4.9 ng/mL) than in the healthy control group (6.0 ng/mL). In addition, participants in the LTBI group with a history of being infected (9.6 ng/mL) with the COVID-19 had higher PAI-1 levels than those who had never been infected (2.3 ng/mL), which is statistically significant (P = 0.004). Although there was no statistically significant difference (P > 0.05) in PAI-1 levels among participants in the healthy control group, those with a history of being infected (6.7 ng/mL) demonstrated higher PAI-1 levels than those who had never been infected (4.8 ng/mL).
Conclusions: PAI-1 levels were lower in LTBI participants than in healthy control participants, which potentially is due to more participants in the healthy control group having a history of COVID-19 infection.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Sotgiu G, Centis R, D’ambrosio L, Migliori GB. Tuberculosis treatment and drug regimens. Cold Spring Harbor Perspect Med. 2015;5(5):a017822. DOI: https://doi.org/10.1101/cshperspect.a017822
World Health Organization. Global Tuberculosis Report 2018. Geneva: World Health Organization; 2018. Available from: https://www.who.int [Last accessed on 2022 Apr 20].
Kemenkes RI. [Infodatin: Found tuberculosis and treat until recovered]. Infodatin: Tuberkulosis Temukan Obati Sampai Sembuh. Jakarta: Pusat Data dan Informasi Kementerian Kesehatan RI; 2018. Available from: https://pusdatin.kemkes.go.id [Last accessed on 2022 Feb 22].
Jeong YJ, Lee KS, Yim JJ. The diagnosis of pulmonary tuberculosis: A Korean perspective. Prec Future Med. 2017;1(2):77-87. DOI: https://doi.org/10.23838/pfm.2017.00114
Hamidah RW, Made MN, Soedarsono S. Risk factors of latent tuberculosis infection in healthcare workers at hospitals in jember city indonesia. Afr J Infect Dis. 2021;15(1):34-40. https://doi.org/10.21010/ajid.v15i1.4 PMid:33884356 DOI: https://doi.org/10.21010/ajid.v15i1.4
Kothari H, Keshava S, Vatsyayan R, Mackman N, Rao LV, Pendurthi UR. Role of tissue factor in Mycobacterium tuberculosis-induced inflammation and disease pathogenesis. PLoS One. 2014;9(12):e114141. https://doi.org/10.1371/journal.pone.0114141 DOI: https://doi.org/10.1371/journal.pone.0114141
Lasierra-Cirujeda J, Coronel P, Aza PM, Gimeno M, Aza PM. Stress/inflammation and pai-1 as stellar processes in the aging and associated pathologies. Integr Mol Med. 2018;5(1):1-2.
Cesari M, Pahor M, Incalzi RA. Plasminogen activator inhibitor‐1 (PAI‐1): A key factor linking fibrinolysis and age‐related subclinical and clinical conditions. Cardiovasc Ther. 2010;28(5):e72-91. https://doi.org/10.1111/j.1755-5922.2010.00171.x PMid:20626406 DOI: https://doi.org/10.1111/j.1755-5922.2010.00171.x
Gleerup G, Winther K. The effect of ageing on platelet function and fibrinolytic activity. Angiology. 1995;46(8):715-8. https://doi.org/10.1177/000331979504600810 PMid:7639418 DOI: https://doi.org/10.1177/000331979504600810
Eriksson P, Reynisdottir S, Lönnqvist F, Stemme V, Hamsten A, Arner P. Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals. Diabetologia. 1998;41(1):65-71. https://doi.org/10.1007/s001250050868 PMid:9498632 DOI: https://doi.org/10.1007/s001250050868
Smith LH, Coats SR, Qin H, Petrie MS, Covington JW, Su M, et al. Differential and opposing regulation of PAI-1 promoter activity by estrogen receptor α and estrogen receptor β in endothelial cells. Circ Res. 2004;95(3):269-75. https://doi.org/10.1161/01.RES.0000136521.70093.f1 PMid:15217907 DOI: https://doi.org/10.1161/01.RES.0000136521.70093.f1
Shitrit D, Izbicki G, Shitrit AB, Raz M, Sulkes J, Kramer MR. Normal D-dimer levels in patients with latent tuberculosis infection. Blood Coagul Fibrinolysis. 2005;16(1):85-7. https://doi.org/10.1097/00001721-200501000-00014 PMid:15650552 DOI: https://doi.org/10.1097/00001721-200501000-00014
Kager LM, Blok DC, Lede IO, Rahman W, Afroz R, Bresser P, et al. Pulmonary tuberculosis induces a systemic hypercoagulable state. J Infect. 2015;70(4):324-34. https://doi.org/10.1016/j.jinf.2014.10.006 PMid:25455017 DOI: https://doi.org/10.1016/j.jinf.2014.10.006
Nkansah C, Addai-Mensah O, Mensah K, Owusu M, Ephraim RKD, Adu P, et al. Plasminogen activator inhibitor-1 in poorly controlled vs well controlled Type-2 diabetes mellitus patients: A case-control study in a district hospital in Ghana. PLoS One. 2021;16(4):e0250090. https://doi.org/10.1371/journal.pone.0250090 PMid:33857223 DOI: https://doi.org/10.1371/journal.pone.0250090
Gebara OC, Mittleman MA, Sutherland P, Lipinska I, Matheney T, Xu P, et al. Association between increased estrogen status and increased fibrinolytic potential in the Framingham offspring study. Circulation. 1995;91(7):1952-8. DOI: https://doi.org/10.1161/01.CIR.91.7.1952
Yanti AK. [Relationship between plasminogen activator inhibitor-1 serum levels with the control degree in Asthma patient]. Hubungan antara kadar plasminogen activator inhibitor-1 serum dengan derajat kontrol penderita Asma. UMI Med J. 2018;3(1):12-23. DOI: https://doi.org/10.33096/umj.v3i1.31
Somodi S, Seres I, Lőrincz H, Harangi M, Fülöp P, Paragh G. Plasminogen activator inhibitor-1 level correlates with lipoprotein subfractions in obese nondiabetic subjects. Int J Endocrinol. 2018;2018:9596054. https://doi.org/10.1155/2018/9596054 PMid:30002679 DOI: https://doi.org/10.1155/2018/9596054
Andrianto A, Rizkiawan R, Harsoyo PM. COVID-19 and endothelial dysfunction: Biomarkers and potential drug mechanisms. Indones J Trop Infect Dis. 2021;9(2):108-19. DOI: https://doi.org/10.20473/ijtid.v9i2.25489
Kwaan HC, Lindholm PF. The central role of fibrinolytic response in COVID-19-a hematologist’s perspective. Int J Mol Sci. 2021;22(3):1283. https://doi.org/10.3390/ijms22031283 PMid:3352544 DOI: https://doi.org/10.3390/ijms22031283
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2022 Sanrio Neuro Tonapa, Nur Ahmad, Sahyuddin Saleh, Syakib Bakri, Rahmawati Minhajat, Fardah Akil, Arifin Seweng (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
